The purpose of this K23 proposal is to provide Tara I. Chang, MD, MS with the protected time and resources to allow her to pursue the additional training needed to reach her long-term goal of becoming an independent patient-oriented investigator. Dr. Chang is a board-certified nephrologist and trained epidemiologist, and her research focuses on the intersection of cardiovascular disease and chronic kidney disease (CKD). Chronic kidney disease confers an increased risk for cardiovascular morbidity and mortality, and cardiovascular disease is the leading cause of death in CKD. Visit-to-visit blood pressure variability (BPV), defined as variation in blood pressure that occurs over days to months, is emerging as an important risk factor for death and cardiovascular events independent of mean or usual blood pressure in patients without CKD. Relatively little is known about visit-to-visit BPV in patients with CKD, a population at high risk for adverse clinical event. In addition, to date there is no uniform metric used to characterize visit-to-visit BPV. This projet proposes a series of analyses in patients with CKD, including end-stage renal disease (ESRD), to close some of the evidence gaps related to determinants and consequences of visit-to-visit BPV in this population.
The specific aims of this project are to define the best metrics of visit-t-visit BPV;better characterize traditional and patient-centered determinants of visit-to-visit BPV; compare the effectiveness of antihypertensive medications on clinical outcomes and evaluate whether differences are mediated by differences in visit-to-visit BPV;and evaluate the incremental prognostic value of visit-to-visit BPV as a novel risk marker beyond systolic, diastolic, or mean arterial blood pressure. The proposed work has high potential to make a significant clinical impact, as completion of the project aims will not only advance the current understanding of visit-to-visit BPV in CKD, but also provide preliminary data on putative risk factors to target in a future intervention trial aimed at lowering visit-to-visit BPV and improving clinical outcomes. Importantly, the proposed work is realistic and feasible within the award period, and will allow Dr. Chang to continue to build research skills, generate preliminary data, create additional collaborative networks, and compete for R01 funding. In summary, the K23 award will support the proposed training and career development activities to allow Dr. Chang to launch successfully into the next phase of her career as an independent clinical investigator.

Public Health Relevance

Blood pressure can fluctuate a great deal from one day to the next (a phenomenon known as visit-to-visit blood pressure variability), and this variability may be a risk factor for heart disease, stroke, death, and other important clinical outcomes. Currently, not much is known about visit-to-visit blood pressure variability, particularly in persos with kidney disease, who are at very high risk of cardiovascular disease and other adverse outcomes. The current proposal aims to shed some light on this important topic by evaluating the determinants and consequences of visit-to-visit blood pressure variability in persons with kidney disease.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-G (M2))
Program Officer
Rankin, Tracy L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Tuohy, C Vaughan; Montez-Rath, Maria E; Turakhia, Mintu et al. (2016) Sleep disordered breathing and cardiovascular risk in older patients initiating dialysis in the United States: a retrospective observational study using medicare data. BMC Nephrol 17:16
Chang, Tara I; Tabada, Grace H; Yang, Jingrong et al. (2016) Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease. J Hypertens 34:244-52
Chang, Tara I; Zheng, Yuanchao; Montez-Rath, Maria E et al. (2016) Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis. Clin J Am Soc Nephrol 11:1401-12
Chang, Tara I; Montez-Rath, Maria E; Tsai, Thomas T et al. (2016) Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis. J Am Coll Cardiol 67:1459-69
Shen, Jenny I; Lum, Erik L; Chang, Tara I (2016) Balancing the Evidence: How to Reconcile the Results of Observational Studies vs. Randomized Clinical Trials in Dialysis. Semin Dial 29:342-6
Chang, Tara I; Evans, Gregory; Cheung, Alfred K et al. (2016) Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. Hypertension 67:550-5
Hong, K; Muntner, P; Kronish, I et al. (2016) Medication adherence and visit-to-visit variability of systolic blood pressure in African Americans with chronic kidney disease in the AASK trial. J Hum Hypertens 30:73-8
Shen, Jenny I; Saxena, Anjali B; Montez-Rath, Maria E et al. (2016) Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use and cardiovascular outcomes in patients initiating peritoneal dialysis. Nephrol Dial Transplant :
Shen, Jenny I; Montez-Rath, Maria E; Lenihan, Colin R et al. (2015) Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. Am J Kidney Dis 66:677-88
Winkelmayer, Wolfgang C; Chang, Tara I; Mitani, Aya A et al. (2015) Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis 66:106-13

Showing the most recent 10 out of 12 publications